DAX23.739 +0,9%ESt505.500 +1,0%Top 10 Crypto15,32 +0,4%Dow46.247 +0,7%Nas22.484 +0,4%Bitcoin93.452 -0,3%Euro1,1704 ±0,0%Öl69,75 +0,2%Gold3.763 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Lufthansa 823212 Tesla A1CX3T RENK RENK73 Novo Nordisk A3EU6F DroneShield A2DMAA Intel 855681 HENSOLDT HAG000 Allianz 840400 Amazon 906866 Siemens Energy ENER6Y Deutsche Telekom 555750 Volkswagen (VW) vz. 766403 SAP 716460
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach US-Inflationsdaten: DAX geht höher ins Wochenende -- US-Börsen fest -- Höhere Trump-Zölle auf Arzneimittel & Co. -- Gerresheimer, Intel, Plug Power, Siemens, Rheinmetall, D-Wave, Oracle im Fokus
Top News
Wie viel Verlust bei einem Investment in Hedera von vor 5 Jahren angefallen wäre Wie viel Verlust bei einem Investment in Hedera von vor 5 Jahren angefallen wäre
Wie viel eine Toncoin-Investition von vor 5 Jahren gekostet hätte Wie viel eine Toncoin-Investition von vor 5 Jahren gekostet hätte
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Jetzt 3-fach-Bonus sichern bei finanzen.net zero und dauerhaft Gebühren sparen!

Viking Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
21,78 EUR +0,26 EUR +1,21 %
BMN
25,45 USD -0,11 USD -0,43 %
nachbörslich
BTT
Viking Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.2,41 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA12GD6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS92686J1060

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVKTX

Viking Therapeutics Aktien News

DatumMeistgelesen
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
PR NewswireViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
PR NewswireViking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Wer­bungViking Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireViking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
PR NewswireViking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
PR NewswireViking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
PR NewswireViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
PR NewswireViking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
PR NewswireViking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
PR NewswireViking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
PR NewswireViking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
PR NewswireViking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
PR NewswireViking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
PR NewswireViking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
PR NewswireViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
PR NewswireViking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
PR NewswireViking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
PR NewswireViking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
PR NewswireViking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
PR NewswireViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
PR NewswireViking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
PR NewswireViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
PR NewswireViking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
PR NewswireViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
PR NewswireViking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

Viking Therapeutics News

Viking Therapeutics News: auf dieser Seite finden Sie alle Viking Therapeutics News und Nachrichten zur Viking Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viking Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viking Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.